This bill reforms Medicare's payment system for skin substitute products—materials applied to wounds to promote healing—starting January 1, 2026. The legislation establishes a new standardized payment rate based on a volume-weighted average of current Medicare payments, with annual adjustments tied to inflation, ensuring consistent reimbursement across different care settings. To protect program integrity, the bill requires Medicare to identify the top 3 percent of providers billing for skin substitutes and subject them to prepayment claim reviews and prior authorization requirements, with a $5 million annual funding allocation through 2030 for oversight activities. The bill also requires the FDA to review and streamline its approval process for human tissue products within 18 months and issue updated guidance within 24 months, aiming to reduce unnecessary duplicative requirements while maintaining safety standards. Overall, the legislation seeks to improve patient access to advanced wound care products while preventing fraud and abuse in the Medicare program.